Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
US-based phase III commercial facility to support client base with large scale production of oral solid dosage forms.
August 30, 2021
By: Tim Wright
Editor-in-Chief, Contract Pharma
BioDuro-Sundia, a drug discovery and development services organization, has acquired a 40,000 square foot commercial oral solid dose manufacturing facility located at 72 Fairbanks, Irvine, CA. BioDuro-Sundia expects to begin commercial service operations at the site on January 1, 2022. “This fully-audited and operational facility allows us to immediately support our clients who require larger scale commercial production,” said Kent Payne, president, development and manufacturing US/EU at BioDuro-Sundia. “BioDuro-Sundia is a pioneer in enhancing bioavailability, with 25 years of experience applying stabilized amorphous solid dispersion technology to poorly soluble drug product candidates. Our clients have requested our support to provide commercial scale manufacturing to save time and maximize success, and it is a pleasure to take this next step with them.” Capabilities of the new site include more than 1 billion unit annual capacity in tableting and encapsulation, as well as aqueous and organic solvent process for fluid bed and coating capabilities. BioDuro-Sundia is making new equipment investments in support of the commercial operation, including commercial spray drying capacity up to 100kg/hr and hot melt extrusion capacity up to 30kg/hr. These capabilities provide a commercial extension to the company’s existing oral solid development and manufacturing capabilities. “We are dedicated to our clients through all phases of drug discovery, development and manufacturing,” said Payne. “This means continued investment in our capabilities as we have done at our new 150,000 square foot R&D site in Wuxi City, China last year, and now our U.S.-based commercial drug product manufacturing site. In partnership with our investors, Advent International, we are committed to accelerating growth to support clients from discovery through to commercialization. The results are good for all stakeholders, and especially critical for our pharma partners who benefit from integrated services with time savings and quality drug product.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !